Clicky

 

Intelligence » Leukemia » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Promising responses seen with Agios leukemia drug in study

Monday, December 11, 2017 -- (Reuters) - Nearly a third of patients with an advanced form of a fast-progressing leukemia who carry a specific genetic mutation experienced a complete or near complete response to an experimental Agios Pharmaceuticals drug, according to data from an early stage trial released on Monday.

Amgen's Kyprolis improves overall survival in blood cancer patients

Monday, December 11, 2017 -- (Reuters) - Amgen Inc said on Monday a final analysis of late-stage trial data showed that its Kyprolis combined with two other drugs helped blood cancer patients live longer.

Novartis’ Kymriah shows durable response in blood cancer

Monday, December 11, 2017 -- New analysis of trial data on Novartis’ CAR-T therapy Kymriah presented at the 59th American Society of Hematology (ASH) annual meeting show that the drug sustained complete responses at six months in adults with a difficult to treat form of blood cancer.

Scientists develop software that predicts leukemia-specific immune targets

Monday, December 11, 2017 -- University of North Carolina Lineberger Comprehensive Cancer Center scientists have developed a software program that can accurately predict which tumor-specific markers will show up on the surface of leukemia cells in patients who have received stem cell transplants.

IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients

Saturday, December 09, 2017 -- (MENAFN Editorial) NORTH CHICAGO, Ill., Dec. 9, 2017 /PRNewswire/ --AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new three-year follow-up data from the ...

Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases Nasdaq:BLCM

Saturday, December 09, 2017 -- (MENAFN Editorial) ATLANTA, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:), a leader in developing novel, controllable cellular immunotherapies for canc...

Venetoclax Improves Outcomes vs Bendamustine in Chronic Lymphocytic Leukemia

Tuesday, December 12, 2017 -- Researchers randomly assigned 389 patients with R/R CLL to VR or BR study arms. Patients were stratified by del(17p) status, responsiveness to previous therapy, and geographic region.

Nilotinib Dose, Frequency Reduction Maintains Efficacy in Chronic Myeloid Leukemia

Sunday, December 10, 2017 -- Researchers analyzed the outcomes of 67 patients with BCR-ABL1-positive CML in chronic phase who had an MMR on nilotinib twice daily and who then switched to a once-daily reduced-dose regimen.

Radotinib May Yield Superior Outcomes to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia

Sunday, December 10, 2017 -- Researchers randomly assigned 241 patients to receive radotinib 300 mg twice daily, radotinib 400 mg twice daily, or imatinib 400 mg once daily.

Changing Therapeutic Landscape for Chronic Lymphocytic Leukemia

Monday, December 11, 2017 -- Danelle James, MD, discusses the changing landscape at the ASH 2017 meeting in Atlanta.

New Developments in Ibrutinib for Chronic Lymphocytic Leukemia

Saturday, December 09, 2017 -- Alessandra Tedeschi, MD, discusses the latest findings on ibrutinib for treatment of chronic lymphocytic leukemia (CLL).

Venetoclax Plus Rituximab for Chronic Lymphocytic Leukemia

Tuesday, December 12, 2017 -- Gary Gordon, MD, PhD, discusses latest findings at the ASH 2017 meeting in Atlanta.

Acute Leukemia: Highlights from ASH 2017

Saturday, December 09, 2017 -- Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.

Relapsed Ph-Negative Acute Lymphoblastic Leukemia Incurs a High Economic Burden

Tuesday, December 12, 2017 -- Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.

Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases

Saturday, December 09, 2017 -- ATLANTA, Dec. 09, 2017 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced results from...

Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia

Sunday, December 10, 2017 -- – Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine evaluable patients with...

Shire plc New Formulation of ONCASPAR pegaspargase Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia ALL

Wednesday, December 13, 2017 -- New Formulation of ONCASPAR® (pegaspargase) Receives Marketing Authorization in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) Freeze-dried, or lyophilized, formulation aims to improve supply management...

FDA researchers find underrepresentation of adults aged 75 years and older in blood cancer clinical trials

Wednesday, December 13, 2017 -- In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.

Transfusion dependence reduces access to high-quality end-of-life care for leukemia patients

Thursday, December 14, 2017 -- For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented during the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta.